{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-002184","form_type":"8-K","ticker":"QTRX","cik":"0001503274","company_name":"Quanterix Corp","filed_at":"2024-02-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:24.362545+00:00","generated_at":"2026-06-05T06:33:46.247591+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Quanterix Q4 revenue up 22% to $31.5M, net loss narrows; guides FY2024 revenue $139-144M","bullets":["Q4 revenue $31.5M (+22% YoY); GAAP gross margin 53.2% (up from 48.8%); net loss $12.4M vs $18.6M.","Full-year 2023 revenue $122.4M (+16%); GAAP gross margin 57.7% vs 44.4%; net loss $32.3M vs $96.7M.","Completed corporate transformation; new assays in production. Collaborations with Mayo Clinic, Mass General Brigham, others for Alzheimer's diagnosis.","2024 guidance: revenue $139-144M (research-only), GAAP gross margin 57-61%, non-GAAP 51-55%, cash usage $25-30M.","Eli Lilly launched pTau217 blood-based diagnostic test on Quanterix platform."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-002184","json":"https://secwatch.observer/filing/0001558370-24-002184.json","markdown":"https://secwatch.observer/filing/0001558370-24-002184.md","text":"https://secwatch.observer/filing/0001558370-24-002184.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503274/000155837024002184/0001558370-24-002184-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503274/000155837024002184/tmb-20240229x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-05T06:33:46.247591+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c11031d9fbf2aa0dabe205c4d765dc2e643394ee","claim":"Quanterix Corp reported the fourth quarter and twelve months ended December 31, 2023 results: revenue $31.5 million, net income Net loss was $12.4 million. Guidance initiated.","evidence_excerpt":"biomarker testing to support the rollout of new Alzheimer’s therapies and to aid providers in the diagnosis of the disease.” Fourth Quarter Financial Highlights ● Revenue was $31.5 million, a 22% increase from $25.8 million for the corresponding prior year period. ● GAAP gross margin was 53.2% as compared to 48.8% for the corresponding prior year period. Non-GAAP","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1503274/000155837024002184/0001558370-24-002184-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and twelve months ended December 31, 2023"},{"label":"Revenue","value":"$31.5 million"},{"label":"Net income","value":"Net loss was $12.4 million"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}